EVAX
Evaxion Biotech A/SNASDAQHealthcare$3.73-1.42%ClosedMarket Cap: $23.5M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
3.12
EV/EBITDA
-0.90
DCF Value
$40.68
FCF Yield
-28.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-122.7%
Net Margin
-102.4%
ROE
-61.6%
ROA
-27.2%
ROIC
-33.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $22.0K | -34160.6% | $-4.1M | $-5.9M | $-0.89 | — |
| FY 2025 | $7.6M | 99.7% | $-9.3M | $-7.7M | $-1.21 | — |
| Q3 2025 | $7.5M | 100.0% | $3.0M | $4.6M | $4.20 | — |
| Q2 2025 | $37.0K | 100.0% | $-4.3M | $-4.8M | $-4.40 | — |
| Q1 2025 | $0.00 | NaN% | $-3.9M | $-1.6M | $-0.50 | — |
| Q4 2024 | $122.0K | 100.0% | $-4.0M | $-3.6M | $-3.40 | — |
| FY 2024 | $3.3M | 100.0% | $-14.7M | $-10.6M | $-9.80 | — |
| Q3 2024 | $3.0M | 100.0% | $-1.7M | $-1.9M | $-1.40 | — |
| Q2 2024 | $154.0K | 100.0% | $-4.6M | $-6.2M | $-4.60 | — |
| Q1 2024 | $51.0K | 100.0% | $-4.4M | $1.2M | $1.04 | — |
| Q4 2023 | $73.0K | 100.0% | $-4.4M | $-4.5M | $-6.60 | — |
| FY 2023 | $73.0K | 100.0% | $-22.2M | $-22.1M | $-32.40 | — |